The utilization of molecular typing, specifically with regards to the estrogen and progesterone receptors (ER and PR), human epidermal growth factor receptor 2 (HER-2), and other markers, has significantly enhanced the precision of treatment for BC. The gene discussed is ERBB2; the disease is breast cancer.